N/A
Manufactured by Allergan, Inc.
22,264 FDA adverse event reports analyzed
Last updated: 2026-04-14
CARBOXYMETHYLCELLULOSE SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Allergan, Inc.. The most commonly reported adverse reactions for CARBOXYMETHYLCELLULOSE SODIUM include DRUG INEFFECTIVE, EYE PAIN, MACULAR DEGENERATION, EYE IRRITATION, OFF LABEL USE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CARBOXYMETHYLCELLULOSE SODIUM.
Out of 8,881 classified reports for CARBOXYMETHYLCELLULOSE SODIUM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 22,264 FDA FAERS reports that mention CARBOXYMETHYLCELLULOSE SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, EYE PAIN, MACULAR DEGENERATION, EYE IRRITATION, OFF LABEL USE, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Allergan, Inc. in connection with CARBOXYMETHYLCELLULOSE SODIUM. Always verify the specific product and NDC with your pharmacist.